{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:50:26Z","timestamp":1761094226630,"version":"build-2065373602"},"reference-count":53,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (HCT) remains the only curable option for adult patients with hematologic malignancies. According to guidelines published by the American Society for Transplantation and Cellular Therapy, allogeneic HCT should be offered to all intermediate\u2010 and high\u2010risk patients with acute leukemia. While matched\u2010related donor (MRD) grafts continue to be the preferred stem cell source for allogeneic HCT, studies comparing MRD grafts to matched\u2010unrelated donor (MUD) grafts showed comparable outcomes in patients with acute leukemia. Unfortunately, for those without a suitable matched\u2010related graft, the probability of finding a suitable matched\u2010unrelated donor varies significantly depending on racial and ethnic background. With allogeneic HCT procedures increasing year after year due to the increased availability of suitable donors, each of these alternative donor sources merits special clinical considerations, specifically with regard to infections. Infections remain a significant cause of morbidity and mortality after allogeneic transplant, especially in those receiving alternative donor grafts. Due to the high\u2010risk nature associated with these donor grafts, it is important to understand the true risk of developing infectious complications. While there are a multitude of infections that have been described in patients post\u2010allogeneic HCT, this review seeks to focus on the incidence of cytomegalovirus (CMV) and invasive fungal infections (IFI) in adult patients receiving alternative donor source transplantation for hematologic malignancies.<\/jats:p>","DOI":"10.1002\/phar.2433","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T16:25:07Z","timestamp":1591287907000},"page":"773-787","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Incidence of viral and fungal complications after utilization of alternative donor sources in hematopoietic cell transplantation"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3184-7362","authenticated-orcid":false,"given":"Laura K.","family":"Whited","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria W.","family":"Handy","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Chow","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC Horsham Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.032"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-381699"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30737"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1311707"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu364"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.963079"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz037"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0624-z"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.229"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.06.012"},{"issue":"1","key":"e_1_2_5_12_1","first-page":"98","article-title":"Infectious complications in cord blood and T\u2010cell depleted haploidentical stem cell transplantation","volume":"1","author":"Mulanovich VE","year":"2011","journal-title":"Am J Blood Res"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.029"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639831"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3523"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2423-y"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12629"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12365"},{"issue":"1","key":"e_1_2_5_19_1","doi-asserted-by":"crossref","first-page":"e13206","DOI":"10.1111\/tid.13206","article-title":"and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post\u2010transplantation cyclophosphamide","volume":"22","author":"Huntley D","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13096"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.08.003"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1500897"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-143560"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702450"},{"issue":"6","key":"e_1_2_5_25_1","first-page":"783","article-title":"CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections","volume":"13","author":"Bacigalupo A","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-3-199302010-00004"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361618"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703916"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.018"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.10.011"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2222-x"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.89"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13070"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0369-0"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2016.02.005"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.008"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.029"},{"key":"e_1_2_5_38_1","unstructured":"D'SouzaA FrethamC.Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides 2018. Available fromhttps:\/\/www.cibmtr.org. Accessed November 11 2019."},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13187"},{"key":"e_1_2_5_41_1","doi-asserted-by":"crossref","first-page":"e13866","DOI":"10.1111\/ctr.13866","article-title":"Clinical, \"real\u2010world\" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients","author":"Anderson A","year":"2020","journal-title":"Clin Transplant"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0730-y"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.07.003"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0475-7"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13202"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00893-18"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.254"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.02.018"},{"issue":"12","key":"e_1_2_5_52_1","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on infections in Leukaemia","volume":"73","author":"Maertens JA","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx450"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2433","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:08:58Z","timestamp":1761059338000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/phar.2433"],"URL":"https:\/\/doi.org\/10.1002\/phar.2433","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"2020-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}